Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model

doi:10.3748/wjg.v28.i32.4620

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4360)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-5) series.

Item

Count

PDF

163

WORD

HTML

1540

Figures (1-6)

429

Tables (1-5)

335

Sum=2511

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

182

Download

386

Sum=568

Publishing Process of This Article

Item

Count

Browse

320

Download

961

Sum=1281

Aug 28, 2022 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Aug 28, 2022; 28(32): 4620-4634
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4620

Table 4 Haematological parameters in different treatment groups

No.	Group	Hb,g/L	Total RBC as 10¹²/L	PCV, L/L	MCV, fL	MCH, pg	MCHC, g/L	RDW, %	Total WBC as 10⁹/L	N, %	L, %	M, %	E, %	B, %	Plts as 10⁹/L
1	Untreated	121 ± 1.0	7.91 ± 0.9	0.36 ± 0.0	46 ± 1.5	15 ± 0.7	332 ± 1.1	20.6 ± 1.0	5.8 ± 1.3	37 ± 1.0	55 ± 1.1	5 ± 0.8	2 ± 0.1	1 ± 0.0	790 ± 1.2
2	Gemcitabine (10 mg/kg per 3 d)	118 ± 1.4	7.60 ± 1.1	0.38 ± 0.0	50.0 ± 1.8	16.0 ± 0.6	313 ± 1.8	22.1 ± 0.7	6.0 ± 1.2	33.0 ± 1.2	60.0 ± 0.7	6.0 ± 1.3	1.0 ± 0.1	0.0 ± 0.1	720 ± 1.4
3	O.s (200 mg/kg per day)	118 ± 1.5	8.0 ± 0.8	0.38 ± 0.0	48.0 ± 2.0	15.0 ± 1.1	307 ± 0.9	22.3 ± 1.6	6.10 ± 0.7	35.0 ± 0.8	53.0 ± 0.6	9.0 ± 1.0	1.0 ± 0.1	2.0 ± 0.0	801 ± 0.8
4	O.s (200 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination	115 ± 1.7	7.1 ± 1.4	0.35 ± 0.0	50.0 ± 1.6	16.0 ± 0.7	321 ± 1.5	21.5 ± 0.8	5.70 ± 1.5	32.0 ± 0.9	60.0 ± 1.1	5.0 ± 0.7	2.0 ± 0.1	1.0 ± 0.1	760 ± 0.9
5	O.s (400 mg/kg per day)	123 ± 1.6	7.9 ± 0.7	0.36 ± 0.0	46.0 ± 1.5	16.0 ± 1.6	335 ± 2.0	21.0 ± 0.9	5.70 ± 1.8	33.0 ± 1.2	61.0 ± 1.2	4.0 ± 0.6	2.0 ± 0.1	0.0 ± 0.0	740 ± 1.0
6	O.s (400 mg/kg per day) and gemcitabine (10 mg/kg per 3 d) combination	123 ± 1.1	7.70 ± 0.9	0.36 ± 0.0	47.0 ± 1.2	16.0 ± 0.4	331 ± 1.2	22.6 ± 1.3	6.0 ± 1.5	30.0 ± 0.9	60.0 ± 1.1	8.0 ± 1.3	1.0 ± 0.1	1.0 ± 0.0	810 ± 1.3

Results are expressed as mean ± SD (n = 6). The P values in all treated groups were insignificant compared to the untreated group. No statistical difference was also observed among all treatment groups using two-way ANOVA and Tukey’s honest significant difference posthoc test. B: Basophile; E: Eosinophile; Hb: Haemoglobin; L: Lymphocyte; M: Monocyte; MCH: Mean cell haemoglobin; MCHC: Mean cell haemoglobin concentration; MCV: Mean cell volume; N: Neutrophile; O.s: Orthosiphon stamineus; PCV: Packed cell volume; Plts: Platelets; RBC: Red blood cells; RDW: Red cell distribution width; WBC: White blood cells.

Citation: Yehya AHS, Subramaniam AV, Asif M, Kaur G, Abdul Majid AMS, Oon CE. Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model. World J Gastroenterol 2022; 28(32): 4620-4634
URL: https://www.wjgnet.com/1007-9327/full/v28/i32/4620.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i32.4620